These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20456169)

  • 21. The individualisation of glycaemic targets in response to patient characteristics in type 2 diabetes: a scoping review.
    Westall SJ; Narayanan RP; Watmough S; Irving G; Furlong N; McNulty S; Bujawansa S; Hardy K
    Clin Med (Lond); 2022 May; 22(3):257-265. PubMed ID: 35443970
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thiazolidinediones-benefits on microvascular complications of type 2 diabetes.
    Viberti G
    J Diabetes Complications; 2005; 19(3):168-77. PubMed ID: 15866064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current management of diabetes mellitus and future directions in care.
    Chatterjee S; Davies MJ
    Postgrad Med J; 2015 Nov; 91(1081):612-21. PubMed ID: 26453594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glycaemic control in Type 2 diabetes--not for sidelining.
    Narendran P
    Diabet Med; 2008 Jun; 25(6):639-42. PubMed ID: 18544100
    [No Abstract]   [Full Text] [Related]  

  • 25. Review of prandial glucose regulation with repaglinide: a solution to the problem of hypoglycaemia in the treatment of Type 2 diabetes?
    Nattrass M; Lauritzen T
    Int J Obes Relat Metab Disord; 2000 Sep; 24 Suppl 3():S21-31. PubMed ID: 11063281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Medically minimising the impact of hypoglycaemia in type 2 diabetes: a review.
    Noh RM; Graveling AJ; Frier BM
    Expert Opin Pharmacother; 2011 Oct; 12(14):2161-75. PubMed ID: 21668402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antidiabetic agents and endothelial dysfunction - beyond glucose control.
    Eriksson L; Nyström T
    Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):15-25. PubMed ID: 25827165
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE study in a cohort of French patients with type 1 or type 2 diabetes.
    Marre M; Pinget M; Gin H; Thivolet C; Hanaire H; Robert JJ; Fontaine P
    Diabetes Metab; 2009 Dec; 35(6):469-75. PubMed ID: 19914118
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of type 2 diabetes: future approaches.
    Bailey CJ; Day C
    Br Med Bull; 2018 Jun; 126(1):123-137. PubMed ID: 29897499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK.
    Bain SC; Feher M; Russell-Jones D; Khunti K
    Diabetes Obes Metab; 2016 Dec; 18(12):1157-1166. PubMed ID: 27491724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Key considerations around the risks and consequences of hypoglycaemia in people with type 2 diabetes.
    Barnett AH; Cradock S; Fisher M; Hall G; Hughes E; Middleton A
    Int J Clin Pract; 2010 Jul; 64(8):1121-9. PubMed ID: 20236369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Benefits of timely basal insulin control in patients with type 2 diabetes.
    Lovre D; Fonseca V
    J Diabetes Complications; 2015 Mar; 29(2):295-301. PubMed ID: 25536866
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The reality of glycaemic control in insulin treated diabetes: defining the clinical challenges.
    Davies M
    Int J Obes Relat Metab Disord; 2004 Sep; 28 Suppl 2():S14-22. PubMed ID: 15306833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Devoting attention to glucose variability and hypoglycaemia in type 2 diabetes.
    Rutter MK
    Diabetologia; 2018 Jan; 61(1):43-47. PubMed ID: 28913602
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Residual microvascular risk in diabetes: unmet needs and future directions.
    Fioretto P; Dodson PM; Ziegler D; Rosenson RS
    Nat Rev Endocrinol; 2010 Jan; 6(1):19-25. PubMed ID: 19859073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of therapeutic advances on hypoglycaemia in type 2 diabetes.
    Boyle PJ; Zrebiec J
    Diabetes Metab Res Rev; 2008; 24(4):257-85. PubMed ID: 18232062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.
    Rahelić D; Javor E; Lucijanić T; Skelin M
    Ann Med; 2017 Feb; 49(1):51-62. PubMed ID: 27535028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes.
    Paty BW
    Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New frontiers in the management of type 2 diabetes.
    Mudaliar S
    Indian J Med Res; 2007 Mar; 125(3):275-96. PubMed ID: 17496356
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.